MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$5,506,000
EPS
-$6.95
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
Revenue
-0*
Cost of revenues
-0*
Gross profit
-0*
Gain on lease termination
-0*
Research and development
1,915,000 1,039,000*
General and administrative
1,631,000 1,290,750*
Impairment of goodwill
2,044,000 -
Total operating expenses
5,590,000 2,329,750*
Loss from operations
-5,590,000 -2,329,750*
Change in fair value of convertible notes
-0*
Change in fair value to bridge notes derivative liability
-0*
Change in fair value of contingent consideration
-0*
Forward Sales Contract Expense
--1,470,500*
Change in fair value of warrant liabilities
--250*
Interest income
-20,750*
Interest income, net
44,000 -6,750*
Other income, net
-53,750*
Gains Losses On Extinguishment Of Debt
-200,000*
Total other income (expense), net
44,000 -1,202,500*
Loss before income taxes
-5,546,000 -3,532,250*
Benefit (provision) for income taxes
-40,000 -11,250*
Net loss
-5,506,000 -3,521,000*
Series a preferred stock dividend
-4,000*
Net loss attributable to common stockholders
--3,525,000
Basic EPS
-6.95 -0.559
Diluted EPS
-6.95 -0.559
Basic Average Shares
792,000 6,307,000
Diluted Average Shares
792,000 6,307,000
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss-$5,506,000 Benefit (provision) forincome taxes-$40,000 Interest income, net$44,000 Loss before incometaxes-$5,546,000 Total other income(expense), net$44,000 Loss from operations-$5,590,000 Total operatingexpenses$5,590,000 Impairment of goodwill$2,044,000 Research and development$1,915,000 General andadministrative$1,631,000

Ernexa Therapeutics Inc. (ERNAW)

Ernexa Therapeutics Inc. (ERNAW)